

Freedom of Information Request	FOI 22-230	17 <sup>th</sup> June 2022
--------------------------------	------------	----------------------------

**I am researching the usage of high-cost intra-vitreous treatments in Ophthalmology. Your answers to the following questions will be highly appreciated.**

**1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:**

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Ranibizumab**

Please find below the quantities dispensed from the Health Board pharmacies for Ophthalmology (unknown conditions) only for the period January to April 2022. Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Type	Quantity
AFLIBERCEPT (EYLEA) 3.6 mg in 0.09mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	3811
DEXAMETHASONE 700 micrograms Implant 1 Implant Pack	3
RANIBIZUMAB (LUCENTIS) 1.65 mg in 0.165mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	834

**2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.**

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Ranibizumab**

The Health Board does not hold a register of patients treated with the above and would have to review every patient record to determine this. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

- 3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:**

- **Aflibercept**
- **Bevacizumab**
- **Dexamethasone**
- **Ranibizumab**

Please refer to Q2.

- 4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:**

- **Aflibercept**
- **Bevacizumab**
- **Dexamethasone**
- **Ranibizumab**

Please refer to Q2.